0001193125-26-202398
SEC filingOdyssey Therapeutics is a clinical-stage biopharmaceutical company developing oral small-molecule inhibitors targeting innate immune pathways for autoimmune and inflammatory diseases, with lead candidate OD-001 showing proof-of-concept in phase 2a ulcerative colitis trial. This IPO raises ~$205M net proceeds to fund OD-001 phase 2b trials and OD-002 IND-enabling studies into 2028.
Odyssey Therapeutics represents a high-conviction immunology play targeting undrugged innate immune nodes, with OD-001's phase 2a UC data providing clinical validation of its RIPK2 scaffolding inhibitor approach. The 49-patient open-label trial showed concordant improvements across endpoints (e.g., clinical remission, endoscopic response) at both 10mg and 20mg BID doses, with no SAEs or discontinuations, supporting planned phase 2b monotherapy and phase 2a vedolizumab combo trials in H2 2026. This positions OD-001 to potentially break IBD's ~20% remission ceiling, where 45% of responders lose efficacy within 5 years despite 10+ approved therapies. The $205M IPO proceeds extend runway to H2 2028, funding these trials and OD-002 (SLC15A4) phase 1/2a, critical given $148.6M 2025 burn on $127M R&D and $568M accumulated deficit.
Financially, Odyssey has raised $726.5M since 2021 inception, with $217M cash at year-end supporting operations amid expired Pfizer/J&J collaborations ($3M 2025 revenue, down 34% YoY). Post-IPO, 45M shares outstanding imply ~$765M market cap at $17 midpoint, with insiders holding 43% and 180-day lock-ups. Use of proceeds prioritizes OD-001 ($135M) and OD-002 ($50M), reflecting pipeline focus amid no approved products.
Leadership adds credibility: CEO Gary Glick's serial successes (Scorpion $2.5B acquisition, IFM $750M+ deals) and Chair Jeffrey Leiden's Vertex/Abbott track record signal execution capability. Pipeline breadth (OD-003 TNFR2 agonist IND Q1 2027, preclinical TSLP/IL-33, IRAK4) supports 12-18 month clinical entries, leveraging AI/ML and VHH platforms.
Risks center on OD-001 execution (phase 2b topline H2 2027), capital needs (burn may accelerate), competition (TNF/IL-23/integrin therapies), and key-man dependence (Glick's 10hr/week Charm commitment). Going concern note underscores biotech volatility, but strong cash and data de-risk the near-term path.